128 related articles for article (PubMed ID: 36804350)
21. "I want to stay here": Patient and staff perspectives on transitioning from a low-threshold buprenorphine program to clinic-based care.
Martinez NG; Truong AQ; Nordeck CD; Agus D; Genberg BL; Buresh ME
Drug Alcohol Depend; 2024 Apr; 257():111130. PubMed ID: 38452408
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.
Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R
JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340
[TBL] [Abstract][Full Text] [Related]
23. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
[TBL] [Abstract][Full Text] [Related]
24. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
[TBL] [Abstract][Full Text] [Related]
25. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
[TBL] [Abstract][Full Text] [Related]
26. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
Frost MC; Zhang L; Kim HM; Lin LA
JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
[TBL] [Abstract][Full Text] [Related]
27. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.
Mintz CM; Xu KY; Presnall NJ; Hartz SM; Levin FR; Scherrer JF; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211634. PubMed ID: 35544135
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
30. Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study.
Fine DR; Yu L; Triant VA; Baggett TP; Metlay JP
J Gen Intern Med; 2020 Aug; 35(8):2375-2382. PubMed ID: 32206993
[TBL] [Abstract][Full Text] [Related]
31. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
32. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
33. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
34. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
Parlier-Ahmad AB; Pugh M; Martin CE
J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
[TBL] [Abstract][Full Text] [Related]
36. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
Dayal P; Balhara YPS
J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
[TBL] [Abstract][Full Text] [Related]
37. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
[TBL] [Abstract][Full Text] [Related]
38. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
[TBL] [Abstract][Full Text] [Related]
39. Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.
Xu KY; Borodovsky JT; Presnall N; Mintz CM; Hartz SM; Bierut LJ; Grucza RA
Am J Psychiatry; 2021 Jul; 178(7):651-659. PubMed ID: 33653119
[TBL] [Abstract][Full Text] [Related]
40. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Williams AR; Samples H; Crystal S; Olfson M
Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
